research use only
Cat.No.S1143
| Related Targets | VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit |
|---|---|
| Other EGFR Inhibitors | Sunvozertinib Icotinib Hydrochloride AG-1478 Canertinib (CI-1033) Rociletinib (CO-1686) WZ4002 Genistein Poziotinib (NOV120101, HM781-36B) PD153035 PD153035 HCl |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| BC3 | Function Assay | 100 µM | 24 h | mediates PEL cell apoptosis | ||
| BCBL1 | Function Assay | 100 µM | 24 h | mediates PEL cell apoptosis | ||
| BC3 | Function Assay | 100 µM | 24 h | mediates de-phosphorylation of STAT3 correlated with HSP70 and HSF1 reduction | ||
| BCBL1 | Function Assay | 100 µM | 24 h | mediates de-phosphorylation of STAT3 correlated with HSP70 and HSF2 reduction | ||
| BC3 | Function Assay | 100 µM | 24 h | induces a complete autophagic flux | ||
| BCBL1 | Function Assay | 100 µM | 24 h | induces a complete autophagic flux | ||
| SK-MEL-28 | Function Assay | 50/100 µM | 48 h | DMSO | reduces anoikis resistance | |
| MeWo | Function Assay | 50/100 µM | 48 h | DMSO | reduces anoikis resistance | |
| SK-MEL-5 | Function Assay | 50/100 µM | 48 h | DMSO | reduces anoikis resistance | |
| SK-MEL-2 | Function Assay | 50/100 µM | 48 h | DMSO | reduces anoikis resistance | |
| B16-F0 | Function Assay | 50/100 µM | 48 h | DMSO | reduces anoikis resistance | |
| TRPM2/HEK | Function Assay | 0.1–25 µM | 15 min | DMSO | reduces H2O2-induced Ca2+increase in a concentration-dependent manner, and the IC50 value was 1.7 µM | |
| U937 | Function Assay | 0.1–25 µM | 15 min | DMSO | reduces H2O2-induced Ca2+increase in a concentration-dependent manner, and the IC50 value was 0.4 µM | |
| TRPM2/HEK | Function Assay | 10 µM | 40 min | DMSO | reduces TRPM2 activation even at high concentrations of H2O2 | |
| GL37 | Cell Viability Assay | 0-10 µM | 48 h | suppresses La expression | ||
| NRK-52E | Function Assay | 1 µM | 10 min | blocks the stimulatory effect of Ang II on Pax-2 expression | ||
| NRK-52E | Function Assay | 1 µM | 10 min | blocks Ang II induced CD24 expression | ||
| HSC | Function Assay | 20 μM | 1 h | abrogates the differential effects of leptin or AGEs | ||
| EJ | Growth Inhibition Assay | 50/80 μM | 24/48/72 h | inhibits cell growth in both time and dose dependent manner | ||
| EJ | Growth Inhibition Assay | 50/80 μM | 48 h | causes S-phase arrest | ||
| EJ | Function Assay | 50/80 μM | 48 h | downregulates c-Myc, cyclinD1, survivin and VEGF expressions | ||
| HepG2 | Function Assay | 50-500 μM | 60 min | inhibits the IL-6-induced phosphorylation of STAT1 (Tyr705) and STAT3 (Tyr705) in a dose-dependent manner | ||
| SGC7901 | Cell Viability Assay | 0-100 μM | 24/48/72 h | causes a significant reduction in cell viability dose-dependently but not time-dependently | ||
| AGS | Cell Viability Assay | 0-100 μM | 24/48/72 h | causes a significant reduction in cell viability dose-dependently but not time-dependently | ||
| SGC7901 | Function Assay | 50 μM | 24/48/72 h | the levels of pJAK2 began to decline at 24 hr, and rebounded at 72 hr | ||
| AGS | Function Assay | 50 μM | 24/48/72 h | the levels of pJAK2 began to decline at 24 hr, and rebounded at 72 hr | ||
| SGC7901 | Function Assay | 50 μM | 24/48/72 h | the cytoplasmic localization of pJAK2 (JAK2 phosphorylated at residues Tyr1007 and Tyr1008) decreased after AG490 treatment for 24 and 48 hr, but started to rebound at 72 hr | ||
| AGS | Function Assay | 50 μM | 24/48/72 h | the cytoplasmic localization of pJAK2 (JAK2 phosphorylated at residues Tyr1007 and Tyr1008) decreased after AG490 treatment for 24 and 48 hr, but started to rebound at 72 hr | ||
| MC3T3-E1 | Function Assay | 50 μM | 4 h | inhibits HSE-induced BMP7 and GHR protein expression | ||
| 7TD1-DXM | Growth Inhibition Assay | 10 μM | 72 h | DMSO | inhibits cell growth | |
| 7TD1-WD-90 | Growth Inhibition Assay | 10 μM | 72 h | DMSO | inhibits cell growth | |
| 7TD1-DXM | Apoptosis Assay | 50 μM | 48 h | DMSO | induces apoptosis | |
| 7TD1-WD-90 | Apoptosis Assay | 50 μM | 48 h | DMSO | induces apoptosis | |
| 7TD1-WD-90 | Function Assay | 50 μM | 6 h | DMSO | significantly inhibits the phosphorylation of JAK2 and phosphorylation of STAT3 | |
| HepG2 | Function Assay | 100 μM | 12/24 h | inhibits STAT3 tyrosine phosphorylation | ||
| RAW264.7 | Function Assay | 50 μM | 24/48 h | suppresses RANKL-induced osteoclastogenesis | ||
| RAW264.7 | Growth Inhibition Assay | 0-50 μM | 48 h | inhibits cell growth dose-dependently | ||
| RAW264.7 | Growth Inhibition Assay | 0-50 μM | 48 h | causes an arrest of RAW264.7 cells at the G0/G1 phase of the cell cycle | ||
| RAW264.7 | Function Assay | 50 μM | 24/48 h | inhibits RANKL-induced NFATc1 expression and phosphorylation of Ser727STAT3 | ||
| A549 | Function Assay | 20/40 μM | 20 h | 20 μM AG490 suppresses the radiation-induced invasion of A549 cells | ||
| A549 | Function Assay | 10/20/40 μM | 24 h | suppresses the radiation-induced elevation of VEGF | ||
| HUVECs | Cell Viability Assay | 20 µM | 4 h | attenuates H2O2-induced cell shrinkage and improved the attachment rate of the cells | ||
| HUVECs | Apoptosis Assay | 20 µM | 4 h | significantly decreases the cell apoptotic index | ||
| BV-2 | Function Assay | 20 µM | 16 h | inhibits LPS-induced STAT1 phosphorylation with almost completely diminished iNOS expression | ||
| NRK-52E | Function Assay | 5 μM | 30 min | attenuates Ang-(1–7)-inhibited TGF-β1 mRNA at 16 h | ||
| SW620 | Function Assay | 20 µM | 1/6 h | inhibits p-STAT3 activation | ||
| RPE | Function Assay | 30 µM | 3 h | inhibits the induction of p-STAT3 expression | ||
| SW1116 | Function Assay | 100 µM | 24/48/72 h | decreases the expression of JAK2 and pJAK2 time-dependently | ||
| HT29 | Function Assay | 100 µM | 24/48/72 h | decreases the expression of JAK2 and pJAK2 time-dependently | ||
| SW1116 | Function Assay | 100 µM | 24/48/72 h | decreases the pSTAT3 levels in a time-dependent manner | ||
| HT29 | Function Assay | 100 µM | 24/48/72 h | decreases the pSTAT3 levels in a time-dependent manner | ||
| ARPE-19 | Function Assay | 5 μM | 30 min | inhibits JAK2 phosphorilation | ||
| HSC-T6 | Apoptosis Assay | 10 μM | 2 h | inhibits the apoptosis of HSC-T6 cells induced by CDE | ||
| HSC-T6 | Function Assay | 10 μM | 2 h | inhibits the expressions of pY-STAT1 and Bad induced by CDE | ||
| Hep-2 | Growth Inhibition Assay | 25-100 μM | 24/48/72 h | inhibits cell growth in both time and dose dependent manner | ||
| Hep-2 | Apoptosis Assay | 50 μM | 24/48/72 h | induces cell apoptosis time dependently | ||
| Hep-2 | Function Assay | 50 μM | 24/48/72 h | inhibits G1 to S cell cycle transition and induces G1 cell cycle arrest | ||
| Hep-2 | Function Assay | 50 μM | 24/48/72 h | downregulates the STAT3, p-STAT3 and survivin protein levels | ||
| KF8 | Function Assay | 10 μM | 1 h | DMSO | inhibits IL-33-induced NF-κB activation | |
| KF8 | Function Assay | 10 μM | 1 h | DMSO | inhibits IL-33-induced IκBα degradation and NF-κB activation | |
| HEL | Function Assay | 100 μM | 12-72 h | inhibits the level of p-JAK2, JAK2 | ||
| HEL | Growth Inhibition Assay | 100 μM | 0-5 d | reduces growth of JAK2V617F-expressing HEL cells | ||
| A-172 | Function Assay | 50/100 μM | 48 h | reduces the levels of constitutively activated STAT3 in a time-dependent and dose-dependent fashion | ||
| MZ-18 | Function Assay | 50/100 μM | 48 h | reduces the levels of constitutively activated STAT3 in a time-dependent and dose-dependent fashion | ||
| MZ-54 | Function Assay | 50/100 μM | 48 h | reduces the levels of constitutively activated STAT3 in a time-dependent and dose-dependent fashion | ||
| MZ-256 | Function Assay | 50/100 μM | 48 h | reduces the levels of constitutively activated STAT3 in a time-dependent and dose-dependent fashion | ||
| MZ-304 | Function Assay | 50/100 μM | 48 h | reduces the levels of constitutively activated STAT3 in a time-dependent and dose-dependent fashion | ||
| A-172 | Growth Inhibition Assay | 50/100 μM | 48 h | leads to a statistically significant reduction of cell proliferation over a time period of 48 h | ||
| MZ-18 | Growth Inhibition Assay | 50/100 μM | 48 h | leads to a statistically significant reduction of cell proliferation over a time period of 48 h | ||
| MZ-54 | Growth Inhibition Assay | 50/100 μM | 48 h | leads to a statistically significant reduction of cell proliferation over a time period of 48 h | ||
| MZ-256 | Growth Inhibition Assay | 50/100 μM | 48 h | leads to a statistically significant reduction of cell proliferation over a time period of 48 h | ||
| MZ-304 | Growth Inhibition Assay | 50/100 μM | 48 h | leads to a statistically significant reduction of cell proliferation over a time period of 48 h | ||
| A-172 | Function Assay | 50/100 μM | 48 h | inhibits migration | ||
| MZ-18 | Function Assay | 50/100 μM | 48 h | inhibits migration | ||
| MZ-54 | Function Assay | 50/100 μM | 48 h | inhibits migration | ||
| MZ-256 | Function Assay | 50/100 μM | 48 h | inhibits migration | ||
| MZ-304 | Function Assay | 50/100 μM | 48 h | inhibits migration | ||
| A-172 | Function Assay | 100 μM | 48 h | inhibits invasion | ||
| MZ-18 | Function Assay | 100 μM | 48 h | inhibits invasion | ||
| MZ-54 | Function Assay | 100 μM | 48 h | inhibits invasion | ||
| MZ-256 | Function Assay | 100 μM | 48 h | inhibits invasion | ||
| MZ-304 | Function Assay | 100 μM | 48 h | inhibits invasion | ||
| A-172 | Function Assay | 50/100 μM | 48 h | reduces transcription of MMP genes and reduces enzymatic activity of MMPs | ||
| MZ-18 | Function Assay | 50/100 μM | 48 h | reduces transcription of MMP genes and reduces enzymatic activity of MMPs | ||
| MZ-54 | Function Assay | 50/100 μM | 48 h | reduces transcription of MMP genes and reduces enzymatic activity of MMPs | ||
| MZ-256 | Function Assay | 50/100 μM | 48 h | reduces transcription of MMP genes and reduces enzymatic activity of MMPs | ||
| MZ-304 | Function Assay | 50/100 μM | 48 h | reduces transcription of MMP genes and reduces enzymatic activity of MMPs | ||
| SW1990 | Growth Inhibition Assay | 20 μM | 24/48/72 h | inhibits cell growth time dependently | ||
| SW1990 | Function Assay | 20 μM | 24 h | decreases the expression of MMP-2 and VEGF mRNAs | ||
| SW1990 | Function Assay | 20 μM | 24 h | decreases the intensity of p-Stat3 expression | ||
| SW1990 | Invasion Assay | 20 μM | 24 h | reduces invasion of SW1990 cells | ||
| THP1 | Function Assay | 10 uM | 30 min | inhibits STAT3 tyrosine phosphorylation by over 60% | ||
| BMMC | Function Assay | 0-10 μM | 15 min | inhibits LTC4 release in a dose-dependent fashion with near complete inhibition at concentrations ⩾10 μM | ||
| A549 | Function Assay | 15 μm | 1 h | inhibits the phosphorylation of STAT1 on tyrosine 701 was detected 15 min after SPE B treatment | ||
| OVCAR-3 | Function Assay | 10 uM | 1 h | inhibits LPA-induced STAT3 phosphorylation | ||
| PA-1 | Function Assay | 10 uM | 1 h | inhibits LPA-induced STAT3 phosphorylation | ||
| OVCAR-3 | Function Assay | 10 uM | 1 h | inhibits LPA-induced ovarian cancer cell motility | ||
| PA-1 | Function Assay | 10 uM | 1 h | inhibits LPA-induced ovarian cancer cell motility | ||
| Jurkat | Growth Inhibition Assay | 50 μM | 24/48/72 h | enhances TRAIL-induces cell growth inhibition | ||
| SUPT1 | Growth Inhibition Assay | 50 μM | 24/48/72 h | enhances TRAIL-induces cell growth inhibition | ||
| Jurkat | Apoptosis Assay | 50 μM | 24/48 h | enhances TRAIL-induces cell apoptosis | ||
| SUPT1 | Apoptosis Assay | 50 μM | 24/48 h | enhances TRAIL-induces cell apoptosis | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 58 mg/mL
(197.07 mM)
Ethanol : 9 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 294.30 | Formula | C17H14N2O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 133550-30-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Tyrphostin B42, Zinc02557947 | Smiles | C1=CC=C(C=C1)CNC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N | ||
| Targets/IC50/Ki |
JAK2 (V617F)
EGFR
(Cell-free assay) 0.1 μM
|
|---|---|
| In vitro |
AG-490 inhibits HER-2 driven cell proliferation with IC50 of 3.5 μM. Corresponding to the specific dose-dependent inhibition of constitutively activated JAK2 in pre-B acute leukemia (ALL) cells, this compound (5 μM) almost completely blocks the growth of all ALL cells by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. This chemical does not inhibit the activities of Lck, Lyn, Btk, Syk, and Src. It (60-100 μM) blocks the constitutive activation of Stat3sm, and inhibits spontaneous as well as interleukin 2-induced growth of mycosis fungoides (MF) tumor cells with IC50 values of 75 μM and 20 μM, respectively. This compound potently inhibits IL-2-mediated human T cell growth with an IC50 of 25 μM by blocking the activities of JAK3 and STAT5a/b. It significantly inhibits the constitutive activation of Stat3 in MOPC, MPC11, and S194 cells, leading to dramatic dose-dependent apoptosis. This chemical (100 μM) inhibits Akt phosphorylation, inhibits the activation of nuclear factor-κB, and causes the activation of GSK-3β, leading to the reduction of c-Myc. It (50 μM) can induce apoptosis of BaF3 cells expressing T315I and E255K mutants of Bcr-Abl. This compound at 30 μM inhibits not only Epo-induced phosphorylation of wild-type JAK2 but also constitutive phosphorylation of the JAK2 V617F mutant. It also potently inhibits cytokine-independent cell growth induced by the JAK2 V617F mutant in BaF3 cells. |
| Kinase Assay |
In vitro kinase autophosphorylation
|
|
AG-490 is dissolved in DMSO 10%-H2O-ethanol 45%. Crude membrane extracts (0.125 μg/mL) are preactivated with EGF (20 nM) in 50 mM HEPES buffer, pH 7.6, and 125 mM NaCl, for 15 minutes at 4 °C. Autophosphorylation activity of EGFR or ErbB2 kinase is assayed at 4 °C for 30 seconds in V-shaped 96-well plates. Membrane extracts (8 μL) are added to each well containing reaction mixture (12 μL, 50mM, HEPES, pH 7.4,125 mM NaCl, 12 mM M8Ac2, 2 mM MnCl2, 1 mM NaVO3, 1 μM ATP, and 1 μCi[γ-32P]ATP, final concentrations) and increasing concentrations of this compound (4 μL). After termination by addition of hot sample buffer, the samples are run on a 6% SDS-polyacrylamide gel electrophoresis minigel, the gels dried, and autoradiography performed during the linear exposure time period. The receptor bands are scanned densitrometrically, and the results analyzed by the Ez-Fit program. For the analysis of autophosphorylation of JAK2, JAK2 is immunoprecipitated by using anti-JAK2 antibody from lysates of G2 cells pretreated for 16 hours with increasing concentrations of this chemical (0-50 μM). Immune complexes are then immunoblotted with anti-phosphotyrosine antibody. A dose-dependent inhibition of in vitro kinase activity is demonstrated by assessing JAK2 autophosphorylation.
|
|
| In vivo |
Administration of AG-490 drastically reduces the numbers of CD45+ and HLA-DR+ cells from 48 % and 46% in bone marrow of untreated mice, as well as 38% and 22% in the spleen of untreated mice to undetectale levels. In vivo administration of this compound causes murine myeloma tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN-γ production by lymphocytes. Consistent with the in vitro blocking of JAK2 V617F mutant activity, treatment with this chemical at 0.5 mg/day for 10 days effectively inhibits JAK2 V617F mutant-induced tumorigenesis and tumor cell invasion in nude mice. Combined therapy with this agent and IL-12 induces greater antitumor effects than either agent alone in a murine myeloma tumor model. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
I would like to know whether it (S1143) goes to CNS through BBB, or not?
Answer:
It can go through the BBB, as shown in this reference: http://bloodjournal.hematologylibrary.org/content/111/4/2062.full.html.